Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Diabetes and atherogenesis.

× No keyword cloud information.

20 in total

1. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors: E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245

Review 2. Evidence for a specific heart disease of diabetes in humans.

Authors: B M Fisher; B M Frier
Journal: Diabet Med Date: 1990-07 Impact factor: 4.359

3. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Authors: J F Mann; H C Gerstein; J Pogue; J Bosch; S Yusuf
Journal: Ann Intern Med Date: 2001-04-17 Impact factor: 25.391

4. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors: H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal: JAMA Date: 2001-07-25 Impact factor: 56.272

5. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Authors:
Journal: BMJ Date: 1998-09-12

6. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors: B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245

7. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors:
Journal: Lancet Date: 2000-01-22 Impact factor: 79.321

8. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors:
Journal: Lancet Date: 1998-09-12 Impact factor: 79.321

9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors:
Journal: Lancet Date: 1998-09-12 Impact factor: 79.321

10. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial.

Authors:
Journal: Am J Cardiol Date: 1995-05-01 Impact factor: 2.778

10 in total

Review 1. Diabetic heart disease.

Authors: T H Marwick
Journal: Heart Date: 2005-09-13 Impact factor: 5.994

2. Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes.

Authors: T H Schindler; A D Facta; J O Prior; J Cadenas; W A Hsueh; M J Quinones; H R Schelbert
Journal: Heart Date: 2006-08-29 Impact factor: 5.994

3. Characterization of alterations in diabetic myocardial tissue using high resolution MRI.

Authors: Rajaprasad Loganathan; Mehmet Bilgen; Baraa Al-Hafez; Irina V Smirnova
Journal: Int J Cardiovasc Imaging Date: 2005-12-13 Impact factor: 2.357

4. Sphingosine-1-phosphate inhibits high glucose-mediated ERK1/2 action in endothelium through induction of MAP kinase phosphatase-3.

Authors: Angela M Whetzel; David T Bolick; Catherine C Hedrick
Journal: Am J Physiol Cell Physiol Date: 2008-12-17 Impact factor: 4.249

Review 5. [Heart failure in diabetes].

Authors: Michael Resl; Martin Hülsmann; Richard Pacher; Martin Clodi
Journal: Wien Med Wochenschr Date: 2009

Review 6. The diabetic myocardium.

Authors: Thomas H Marwick
Journal: Curr Diab Rep Date: 2006-02 Impact factor: 4.810

Review 7. Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage.

Authors: Nikolas K Haass; Najah Nassif; Eileen M McGowan
Journal: Biomed Res Int Date: 2015-03-19 Impact factor: 3.411

8. Attenuation of atherosclerotic lesions in diabetic apolipoprotein E-deficient mice using gene silencing of macrophage migration inhibitory factor.

Authors: Hui Sun; XianJun Zhang; Lei Zhao; Xi Zhen; ShanYing Huang; ShaSha Wang; Hong He; ZiMo Liu; NaNa Xu; FaLin Yang; ZhongHua Qu; ZhiYong Ma; Cheng Zhang; Yun Zhang; Qin Hu
Journal: J Cell Mol Med Date: 2015-02-08 Impact factor: 5.310

9. Changing the diabetes treatment paradigm from glucose control to cardiorenal protection.

Authors: Preethika Ekanayake; Sunder Mudaliar
Journal: Indian J Med Res Date: 2021-05 Impact factor: 5.274

10. The Cholesterol Metabolite Cholest-5-en-3-One Alleviates Hyperglycemia and Hyperinsulinemia in Obese (db/db) Mice.

Authors: Koji Nagao; Nao Inoue; Kunio Suzuki; Takeshi Shimizu; Teruyoshi Yanagita
Journal: Metabolites Date: 2021-12-29

10 in total